Are CagriSema's REDEFINE-2 trial results concerning? Perhaps not
11/03/25 -"Novo’s investors appeared worried yesterday after its promising obesity/diabetes drug candidate, CagriSema’s, another late-stage trial results yielded weight-loss efficacy which was ..."
Pages
66
Language
English
Published on
11/03/25
You may also be interested by these reports :
04/08/26
BioNTech reported a disappointing quarter, with sales significantly below forecasts and operating losses exceeding expectations. Weaker Covid-19 ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
03/08/26
Astra’s media-reported merger/acquisition talks with Bristol Myers Squibb (BMS) entail worries for Astra’s shareholders – considerable overlapping ...
30/07/26
Ipsen demonstrated robust performance in Q2, exceeding market expectations, which led to an upgraded 2026 guidance. While we may adjust our estimates ...